CD80/86 inhibitors : abatacept

Kevin D. Pile; Garry G. Graham; Stephen M. Mahler

doi:10.1007/978-3-7643-8550-7_20

CD80/86 inhibitors : abatacept

Kevin D. Pile, Garry G. Graham, Stephen M. Mahler

Western Sydney University

Research output: Chapter in Book / Conference Paper › Chapter

Abstract

![CDATA[CD80/CD86 inhibitors are protein constructs which bind and inactivate CD80/CD86 on the surfaces of antigen-presenting B-cells and monocytes, blocking the costimulatory signal between these cells and CD28 on T-cells that is the second message of T-cell receptor/MHC interaction. They are members of a group of proteins commonly termed biological response modifiers (BRMs) or biological disease-modifying antirheumatic drugs (bDMARDs). The major CD80/CD86 inhibitor, abatacept, is not classified as a slow-acting antirheumatic drug (SAARD), because it is considered to have more specific actions and because its therapeutic actions are produced rapidly. Belatacept is a fusion protein which is closely related to abatacept. It is used to prolong kidney grafts.]]

Original language	English
Title of host publication	Compendium of Inflammatory Diseases
Editors	Michael J. Parnham
Place of Publication	Switzerland
Publisher	Springer
Pages	271-274
Number of pages	4
ISBN (Electronic)	9783764385507
ISBN (Print)	9783764385309
DOIs	https://doi.org/10.1007/978-3-7643-8550-7_20
Publication status	Published - 2016

Keywords

antirheumatic agents

Access to Document

10.1007/978-3-7643-8550-7_20

Cite this

@inbook{ae04c2e2512a45efacffd5971b54f563,

title = "CD80/86 inhibitors : abatacept",

abstract = "![CDATA[CD80/CD86 inhibitors are protein constructs which bind and inactivate CD80/CD86 on the surfaces of antigen-presenting B-cells and monocytes, blocking the costimulatory signal between these cells and CD28 on T-cells that is the second message of T-cell receptor/MHC interaction. They are members of a group of proteins commonly termed biological response modifiers (BRMs) or biological disease-modifying antirheumatic drugs (bDMARDs). The major CD80/CD86 inhibitor, abatacept, is not classified as a slow-acting antirheumatic drug (SAARD), because it is considered to have more specific actions and because its therapeutic actions are produced rapidly. Belatacept is a fusion protein which is closely related to abatacept. It is used to prolong kidney grafts.]]",

keywords = "antirheumatic agents",

author = "Pile, {Kevin D.} and Graham, {Garry G.} and Mahler, {Stephen M.}",

year = "2016",

doi = "10.1007/978-3-7643-8550-7_20",

language = "English",

isbn = "9783764385309",

pages = "271--274",

editor = "Parnham, {Michael J.}",

booktitle = "Compendium of Inflammatory Diseases",

publisher = "Springer",

}

TY - CHAP

T1 - CD80/86 inhibitors : abatacept

AU - Pile, Kevin D.

AU - Graham, Garry G.

AU - Mahler, Stephen M.

PY - 2016

Y1 - 2016

N2 - ![CDATA[CD80/CD86 inhibitors are protein constructs which bind and inactivate CD80/CD86 on the surfaces of antigen-presenting B-cells and monocytes, blocking the costimulatory signal between these cells and CD28 on T-cells that is the second message of T-cell receptor/MHC interaction. They are members of a group of proteins commonly termed biological response modifiers (BRMs) or biological disease-modifying antirheumatic drugs (bDMARDs). The major CD80/CD86 inhibitor, abatacept, is not classified as a slow-acting antirheumatic drug (SAARD), because it is considered to have more specific actions and because its therapeutic actions are produced rapidly. Belatacept is a fusion protein which is closely related to abatacept. It is used to prolong kidney grafts.]]

AB - ![CDATA[CD80/CD86 inhibitors are protein constructs which bind and inactivate CD80/CD86 on the surfaces of antigen-presenting B-cells and monocytes, blocking the costimulatory signal between these cells and CD28 on T-cells that is the second message of T-cell receptor/MHC interaction. They are members of a group of proteins commonly termed biological response modifiers (BRMs) or biological disease-modifying antirheumatic drugs (bDMARDs). The major CD80/CD86 inhibitor, abatacept, is not classified as a slow-acting antirheumatic drug (SAARD), because it is considered to have more specific actions and because its therapeutic actions are produced rapidly. Belatacept is a fusion protein which is closely related to abatacept. It is used to prolong kidney grafts.]]

KW - antirheumatic agents

UR - http://handle.westernsydney.edu.au:8081/1959.7/uws:40019

U2 - 10.1007/978-3-7643-8550-7_20

DO - 10.1007/978-3-7643-8550-7_20

M3 - Chapter

SN - 9783764385309

SP - 271

EP - 274

BT - Compendium of Inflammatory Diseases

A2 - Parnham, Michael J.

PB - Springer

CY - Switzerland

ER -

CD80/86 inhibitors : abatacept

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this